Add BrightSurf on Google Email

University of Birmingham


University of Birmingham develops sight-saving treatment for eye infection or trauma

The University of Birmingham has developed an innovative eye drop treatment that rapidly reduces sight-threatening scarring to the surface of the eye. This novel treatment, which consists of a fluid gel loaded with a natural wound-healing protein called Decorin, shows promise in promoting scarless healing and improving corneal transpar...

SourceUniversity of Birmingham·JournalRegenerative Medicine·DateDec 21, 2018

Study discovers over 6,000 antibiotic resistance genes in the bacteria that inhabit the human gut

A recent study has discovered over 6,000 antibiotic resistance genes in bacteria that inhabit the human gut, revealing a vast and previously unknown diversity of resistant genes. The researchers used a novel method to identify these genes by comparing their three-dimensional structures to proteins produced by gut bacteria.

SourceUniversity of Birmingham·JournalNature Microbiology·DateNov 30, 2018

Researchers are one step closer to developing eye drops to treat common sight loss condition

Researchers have made significant progress in developing eye drops to treat age-related macular degeneration (AMD), a leading cause of blindness. The eye drops use cell-penetrating peptides to deliver therapeutic drugs to the retina, offering a convenient and potentially cost-effective alternative to injections.

SourceUniversity of Birmingham·JournalInvestigative Ophthalmology & Visual Science·DateJul 19, 2018

Spinal fluid could be used to predict the progression of multiple sclerosis, study finds

A six-year study by the University of Birmingham has found that analyzing spinal fluid from patients with MS at diagnosis can predict future disease progression. The research identified a distinct immune response, characterized by an unusual antibody ratio, which may indicate early trigger and risk of disability.

SourceUniversity of Birmingham·JournalJournal of Neurology Neurosurgery & Psychiatry·DateMay 9, 2018

Trial shows safety of drugs for irregular heartbeat patients undergoing treatment

Atrial fibrillation affects millions worldwide, increasing risk of stroke and heart failure. A new study finds Apixaban and VKAs safe for treatment during catheter ablation procedures, with a significant improvement in cognitive function. The results will reassure clinicians that continuous Apixaban is an effective alternative to VKAs.

SourceUniversity of Birmingham·JournalEuropean Heart Journal·DateMar 20, 2018